Deep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy

Cancer Immunology Research

Volumn 4, Issue 10, 2016, Pages 835-844

  Page, David B ^a,b   Yuan, Jianda ^a   Redmond, David ^c   Wen, Y Hanna ^a   Durack, Jeremy C ^a   Emerson, Ryan ^d   Solomon, Stephen ^a   Dong, Zhiwan ^a   Wong, Phillip ^a   Comstock, Christopher ^a   Diab, Adi ^e   Sung, Janice ^a   Maybody, Majid ^a   Morris, Elizabeth ^a   Brogi, Edi ^a   Morrow, Monica ^a   Sacchini, Virgilio ^a   Elemento, Olivier ^c   Robins, Harlan ^f   Patil, Sujata ^a   Allison, James P ^e   Wolchok, Jedd D ^a,c   Hudis, Clifford ^a,c   Norton, Larry ^a,c   McArthur, Heather L ^a,c   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b EARLE A CHILES RESEARCH INSTITUTE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d ADAPTIVE BIOTECHNOLOGIES   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IPILIMUMAB; T LYMPHOCYTE RECEPTOR; DNA; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR MARKER;

ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL CLONE; CELL DENSITY; CELL EXPANSION; CLINICAL ARTICLE; CRYOABLATION; DNA SEQUENCE; EARLY CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PREOPERATIVE TREATMENT; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; BIOPSY; BREAST TUMOR; CANCER STAGING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOSURGERY; FEASIBILITY STUDY; GENETICS; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIC INFILTRATION; LYMPHOCYTE COUNT; MASTECTOMY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BIOMARKERS, TUMOR; BIOPSY; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CRYOSURGERY; DNA, NEOPLASM; FEASIBILITY STUDIES; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOTHERAPY; IPILIMUMAB; LEUKEMIC INFILTRATION; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MASTECTOMY; NEOPLASM STAGING; PILOT PROJECTS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SEQUENCE ANALYSIS, DNA;

EID: 84994131409     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-16-0013     Document Type: Article

References (29)

1. Hannani D, Locher C, Yamazaki T, Colin-Minard V, Vetizou M, Aymeric L, et al. Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines. Cell Death Differ 2014; 21: 50-8.
2. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18: 160-70.
3. Clynes R, Knutson KL, Ballman KV, Erskine CL, Norton N, Sumrall SV, et al. Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52. ASCO Meeting Abstracts 2013; 31: 521.
4. Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 2007; 13: 5133-43.
5. Demaria S, Pilones KA, Formenti SC, Dustin ML. Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment. Oncoimmunology 2013; 2: e23127.
6. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26: 259-71.
7. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-7.
8. Gajewski TF Cancer immunotherapy. Mol Oncol 2012; 6: 242-50.
9. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-13.
10. Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, et al. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst 2013; 105: 960-7.
11. Waitz R, Solomon SB, Petre EN, Trumble AE, Fasso M, Norton L, et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res 2012; 72: 430-9.
12. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-6.
13. Gage AA, Baust JM, Baust JG. Experimental cryosurgery investigations in vivo. Cryobiology 2009; 59: 229-43.
14. Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26.
15. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumabinpatients withmetastatic melanoma. N Engl J Med 2010; 363: 711-23.
16. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3: 611-8.
17. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210: 1695-710.
18. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-71.
19. Diab A, McArthur HL, Solomon SB, Sacchini V, Comstock C, Maybody M, et al. A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC). ASCO Meeting Abstracts 2014; 32: 1098.
20. Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 2009; 114: 4099-107.
21. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value oftumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvantbreast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014; 32: 2959-66.
22. Sherwood AM, Emerson RO, Scherer D, Habermann N, Buck K, Staffa J, et al. Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. Cancer Immunol Immunother 2013; 62: 1453-61.
23. Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med 2014; 6: 238ra70.
24. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014; 25: 1544-50.
25. Sabel MS Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology 2009; 58: 1-11.
26. Emens LA Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). AACR Annual Meeting; April 20, 2015; Philidelphia, PA; 2015.
27. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triplenegative breast cancer. San Antonio Breast Cancer Symposium; December 8-13, 2014; San Antonio, TX; 2014.
28. Dirix LY, Takacs I, Nikolinakos P, Jerusalem G, Arkenau H-T, Hamilton EP, et al. Avelumab (MSB00107118C), an anti-PD-L1 antibody, in patients with locally advancedormetastatic breast canceR: A phaseIb JAVELIN solid tumor trial. San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX; 2015.
29. Rugo H, DeLord JP, Im S-A, Ott PA, Piha-Paul SA, Bedard PL, et al. Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1-positive, estrogen receptor positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX; 2015.